In the last 7 years, only 1.9 % trading sessions saw intraday gains higher than 5 % .
Laurus Labs Share Price
Laurus Labs Share Price
Laurus Labs share price insights
Company witnessed QoQ revenue decline of 17.88%, which is lowest in the last 3 years. (Source: Consolidated Financials)
White Spinning Top was formed for Laurus Labs
Stock gave a 3 year return of -28.49% as compared to Nifty Midcap 100 which gave a return of 109.82%. (as of last trading session)
Laurus Labs Ltd. share price moved up by 1.13% from its previous close of Rs 458.75. Laurus Labs Ltd. stock last traded price is 463.90
Share Price Value Today/Current/Last 463.90 Previous Day 458.75
Key Metrics
PE Ratio (x) | 168.76 | ||||||||||
EPS - TTM (₹) | 2.75 | ||||||||||
MCap (₹ Cr.) | 25,011.60 | ||||||||||
Sectoral MCap Rank | 23 | ||||||||||
PB Ratio (x) | 6.01 | ||||||||||
Div Yield (%) | 0.17 | ||||||||||
Face Value (₹) | 2.00 | ||||||||||
Beta Beta
| 1.11 | ||||||||||
VWAP (₹) | 464.68 | ||||||||||
52W H/L (₹) |
Laurus Labs Share Price Returns
1 Day | 1.13% |
1 Week | 6.75% |
1 Month | 9.27% |
3 Months | 3.09% |
1 Year | 31.79% |
3 Years | -27.69% |
5 Years | 590.53% |
Laurus Labs News & Analysis
NewsHot stocks: Brokerage view on Ramco Cements, Tech Mahindra, Laurus Labs, Syngene and Cyient
NewsQ1 results today: Nestle, Tech Mahindra among 76 companies to announce earnings on Thursday
NewsF&O stocks: IDFC First Bank, Aditya Birla Capital among 5 stocks with long buildup
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcements
Laurus Labs Share Recommendations
Recent Recos
Current
Mean Recos by 11 Analysts
SellSellHoldBuyStrong
Buy
That's all for Laurus Labs recommendations. Check out other stock recos.
Analyst Trends
Ratings | Current | 1 Week Ago | 1 Month Ago | 3 Months Ago |
---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 |
Buy | 2 | 3 | 3 | 3 |
Hold | 1 | 1 | 1 | 1 |
Sell | 2 | 1 | 1 | 1 |
Strong Sell | 4 | 4 | 4 | 4 |
# Analysts | 11 | 11 | 11 | 11 |
Laurus Labs Financials
Income (P&L)
Balance Sheet
Cash Flow
Ratios
Insights
Quarterly Topline Performance
Company witnessed QoQ revenue decline of 17.88%, which is lowest in the last 3 years. (Source: Consolidated Financials)Topline Contraction
Sales de-grew by 16.2%. Company witnessed revenue contraction for the first time in last 3 years. (Source: Consolidated Financials)
Quarterly | Annual Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 1,197.42 1,458.20 1,197.35 1,226.23 1,185.39 Total Income Growth (%) -17.88 21.79 -2.36 3.45 -14.26 Total Expenses 1,129.77 1,300.43 1,111.91 1,129.95 1,105.62 Total Expenses Growth (%) -13.12 16.95 -1.60 2.20 -6.49 EBIT 67.65 157.77 85.44 96.28 79.77 EBIT Growth (%) -57.12 84.66 -11.26 20.70 -60.16 Profit after Tax (PAT) 12.51 75.61 23.14 36.95 24.85 PAT Growth (%) -83.45 226.75 -37.37 48.69 -75.87 EBIT Margin (%) 5.65 10.82 7.14 7.85 6.73 Net Profit Margin (%) 1.04 5.19 1.93 3.01 2.10 Basic EPS (₹) 0.23 1.40 0.43 0.69 0.46 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 8,387.03 7,660.40 6,968.04 5,750.69 3,750.32 Total Assets Growth (%) 9.49 9.94 21.17 53.34 12.58 Total Liabilities 4,271.46 3,611.74 3,608.99 3,149.99 1,980.54 Total Liabilities Growth (%) 18.27 0.08 14.57 59.05 11.72 Total Equity 4,115.57 4,048.66 3,359.05 2,600.70 1,769.78 Total Equity Growth (%) 1.65 20.53 29.16 46.95 13.56 Current Ratio (x) 1.23 1.42 1.25 1.25 1.07 Total Debt to Equity (x) 0.61 0.49 0.52 0.51 0.54 Contingent Liabilities 414.14 494.88 481.87 555.75 307.84 All figures in Rs Cr, unless mentioned otherwise
Insights
Decrease in Cash from Investing
Company has used Rs 822.42 cr for investing activities which is an YoY decrease of 17.43%. (Source: Consolidated Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 665.69 993.90 911.10 733.00 347.41 Net Cash used in Investing Activities -822.42 -996.06 -914.34 -940.99 -221.12 Net Cash flow from Financing Activities 249.83 -26.64 30.26 254.70 -127.66 Net Cash Flow 93.27 -29.68 26.89 46.77 -1.28 Closing Cash & Cash Equivalent 138.94 45.67 75.35 48.46 1.69 Closing Cash & Cash Equivalent Growth (%) 204.23 -39.39 55.49 2,770.85 -43.13 Total Debt/ CFO (x) 3.77 1.98 1.90 1.79 2.75 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 3.90 19.56 24.69 37.86 14.42 Return on Capital Employed (%) 7.94 24.37 27.63 41.57 18.62 Return on Assets (%) 1.91 10.31 11.87 17.10 6.80 Interest Coverage Ratio (x) 4.39 9.68 14.26 20.09 4.28 Asset Turnover Ratio (x) 0.63 0.83 0.76 83.70 75.50 Price to Earnings (x) 131.58 20.00 38.46 19.76 13.51 Price to Book (x) 5.14 3.91 9.46 7.48 1.95 EV/EBITDA (x) 29.21 11.09 23.24 13.15 7.72 EBITDA Margin (%) 15.94 26.45 29.09 32.70 20.14
Laurus Labs Peer Comparison
Laurus Labs Stock Performance
Ratio Performance
Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of -28.49% as compared to Nifty Midcap 100 which gave a return of 109.82%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -28.49% return as compared to Nifty Pharma which gave investors 50.26% return over 3 year time period. (as of last trading session)
Choose from Peers
Choose from Stocks
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...Insights
Stock Returns vs Nifty Midcap 100
Stock gave a 3 year return of -28.49% as compared to Nifty Midcap 100 which gave a return of 109.82%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated -28.49% return as compared to Nifty Pharma which gave investors 50.26% return over 3 year time period. (as of last trading session)
See All Parameters
MF Ownership
MF Ownership details are not available.
Corporate Actions
Laurus Labs Board Meeting/AGM
Laurus Labs Dividends
- Others
Meeting Date Announced on Purpose Details Jul 25, 2024 Jul 19, 2024 Board Meeting Quarterly Results Apr 25, 2024 Apr 18, 2024 Board Meeting Audited Results & Interim Dividend Jan 24, 2024 Jan 17, 2024 Board Meeting Quarterly Results Oct 20, 2023 Oct 13, 2023 Board Meeting Quarterly Results & Interim Dividend Jul 27, 2023 Jul 20, 2023 Board Meeting Quarterly Results Type Dividend Dividend per Share Ex-Dividend Date Announced on Interim 20% 0.4 May 08, 2024 Apr 25, 2024 Interim 20% 0.4 Nov 02, 2023 Oct 20, 2023 Interim 60% 1.2 May 10, 2023 Apr 27, 2023 Interim 40% 0.8 Nov 03, 2022 Oct 21, 2022 Interim 60% 1.2 May 10, 2022 Apr 28, 2022 All Types Ex-Date Record Date Announced on Details Splits Sep 29, 2020 Sep 30, 2020 Apr 30, 2020 Split: Old FV10.0| New FV:2.0
About Laurus Labs
Laurus Labs Ltd., incorporated in the year 2005, is a Mid Cap company (having a market cap of Rs 24,715.06 Crore) operating in Pharmaceuticals sector. Laurus Labs Ltd. key Products/Revenue Segments include Pharmaceutical Products, Contract Service, Traded Goods, Other Operating Revenue, Scrap for the year ending 31-Mar-2024. Show More
Executives
Auditors
- RK
Ravindranath Kancherla
Non Exe.Chairman&Ind.DirectorSCSatyanarayana Chava
Executive Director & CEOVVV V Ravi Kumar
Executive Director & CFOCVC V Lakshmana Rao
Executive DirectorShow More - Deloitte Haskins & Sells LLP
Industry
Key Indices Listed on
Nifty Midcap 100, Nifty 200, Nifty 500, + 19 more
Address
Laurus Enclave, Plot Office 01,Edulapakabonangi Village,Parawada Mandal, Anakapalli,Vishakapatnam, Andhra Pradesh - 531021
More Details
FAQs about Laurus Labs share
- 1. What's the Laurus Labs share price today?As on 31 Jul, 2024, 03:58 PM IST Laurus Labs share price was up by 1.13% basis the previous closing price of Rs 446.75. Laurus Labs share price was Rs 463.90. Return Performance of Laurus Labs Shares:
- 1 Week: Laurus Labs share price moved up by 6.75%
- 1 Month: Laurus Labs share price moved up by 9.27%
- 3 Month: Laurus Labs share price moved up by 3.09%
- 6 Month: Laurus Labs share price moved up by 21.65%
- 2. What is Laurus Labs's 52 week high / low?Laurus Labs share price saw a 52 week high of Rs 484.30 and 52 week low of Rs 334.15.
- 3. How can I quickly analyze Laurus Labs stock?Key Metrics for Laurus Labs are:
- PE Ratio of Laurus Labs is 168.76
- Price/Sales ratio of Laurus Labs is 4.19
- Price to Book ratio of Laurus Labs is 6.01
- 4. Which are the key peers to Laurus Labs?Within Pharmaceuticals sector Laurus Labs, Aarti Industries Ltd., J B Chemicals & Pharmaceuticals Ltd., Syngene International Ltd., Piramal Pharma Ltd., Natco Pharma Ltd., Alembic Pharmaceuticals Ltd., Gland Pharma Ltd., Ajanta Pharma Ltd., Suven Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Ltd. are usually compared together by investors for analysis.
- 5. What is the market cap of Laurus Labs?Market Capitalization of Laurus Labs stock is Rs 25,011.60 Cr.
- 6. Who's the owner of Laurus Labs?Following are the key changes to Laurus Labs shareholding:
- Promoter holding have gone down from 27.2 (30 Jun 2023) to 27.19 (31 Mar 2024)
- Domestic Institutional Investors holding has gone up from 10.33 (30 Jun 2023) to 11.78 (31 Mar 2024)
- Foreign Institutional Investors holding has gone up from 22.52 (30 Jun 2023) to 25.98 (31 Mar 2024)
- Other investor holding have gone down from 39.95 (30 Jun 2023) to 35.05 (31 Mar 2024)
Trending in Markets
Laurus Labs Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.